INTRODUCTION
Cholesteryl ester transfer protein (CETP), a member of the Lipid Transfer/Lipopolysaccharide Binding Protein (LT/LBP) family promotes the exchange of neutral lipid species, i.e. cholesteryl esters and triglycerides between plasma lipoproteins. In addition to the concentration of CETP in the plasma compartment, a number of other parameters, including the concentration and composition of lipoprotein substrates can affect the velocity and the extent of the CETP-mediated neutral lipid transfer reaction. In earlier kinetic studies, Barter and Jones (1) and Ihm and colleagues (2) reported that the interactions of CETP with low density lipoproteins (LDL) versus high density lipoproteins (HDL) markedly differ. Hence, at a constant amount of HDL, the rate of the CETP-mediated cholesteryl ester exchange rises with increasing amounts of LDL until a maximal constant value is reached with high LDL to HDL cholesteryl ester ratios. Although at a fixed amount of LDL the rate of cholesteryl ester exchange also tended to increase with moderate amounts of HDL, a potent and significant inhibition of the CETP-mediated lipid transfer process was observed with higher HDL to LDL cholesterol ratios (1, 2) . Initially, the inhibitory effect of HDL has been explained in terms of a greater interaction of CETP with HDL than with LDL, favoring the HDL-HDL exchanges over the LDL-HDL exchanges (1, 2) . More recently, purified HDL apolipoproteins were shown to modulate the cholesteryl ester transfer reaction, and in particular apo A-I and apo A-II, i.e. the two major HDL apolipoproteins were alternatively described as neutral, inhibitory or activating factors of the cholesteryl ester transfer process (3) (4) (5) (6) (7) (8) . In fact, the quest for a CETP inhibitor in plasma HDL over the last decade led to unconsistent observations, and no clear identification and characterization of an
Inhibition of CETP activity by apolipoprotein C-I
inhibitory protein in human HDL has been provided so far. Comparative studies of the ability of HDL from control mice and transgenic mice to human HDL apolipoproteins revealed that the lipid transfer inhibitory activity associated with control mouse HDL can be completely lost as the result of the apo A-I and apo A-II overexpression in the transgenic mouse models (9) . It appears therefore that neither apo A-I nor apo A-II can account for the strong inhibitory activity associated with plasma HDL, and observations in transgenic animals strongly support the existence of a distinct inhibitor protein in the HDL fraction. Recently, Wang and coworkers identified human apo F as a lipid transfer inhibitor protein (10) . It is noteworthy however that apo F is not an HDL apolipoprotein, and no direct evidence for the blockade of lipid transfer inhibitory activity in HDL with anti-apoF antibodies was provided (10) .
Given that the putative lipid transfer inhibitors that were previously proposed are rather heterogenous in terms of molecular weight (ranging from 3 kDa up to 41 kDa (11-16)), the entire spectrum of human HDL apolipoproteins was explored in the present study. This exhaustive experimental approach led to the preparation of up to thirty distinct protein fractions with molecular weights ranging from 2 kDa up to 80 kDa. Among all the isolated proteins, one single candidate was shown to account for most of the lipid transfer inhibitory activity that is associated with human plasma HDL. The present work reports the purification and the characterization of the lipid transfer inhibitory protein in human plasma HDL, providing a new explanation for the known concentration-dependent ability of HDL to inhibit the CETP-mediated lipid transfer process.

MATERIALS AND METHODS
Plasma Samples -Fresh citrated plasmas from normolipidemic subjects were provided by the Etablissement de Transfusion Sanguine (Hôpital du Bocage, Dijon, France).
Antibodies -The anti-human apolipoprotein C-I antiserum from goat was purchased from Europa Research Products. Affinity purified anti-human apo C-I immunoglobulins from goat were purchased from Biodesign International. Affinity purified anti-human apo C-III immunoglobulins were purchased from Rockland.
Isolation of LDL and HDL Particles -LDL were ultracentrifugally isolated from normolipidemic human plasmas as the 1.019 < d < 1.063 g/ml fraction, with one 17-h, 50,000-rpm spin at the lowest density, and one 24-h, 50,000-rpm spin at the highest density in a 70.Ti rotor in a L90-K ultracentrifuge (Beckman). HDL were ultracentrifugally isolated from normolipidemic human plasmas as the 1.070 < d < 1.210 g/ml fraction, with one 24-h, 45,000-rpm spin at the lowest density, and one 24-h, 50,000-rpm spin at the highest density in a 70.Ti rotor in a L90-K ultracentrifuge. Densities were adjusted by the addition of solid KBr. The isolated lipoproteins were dialyzed overnight against a 10 mmol/liter Tris, 150 mmol/liter NaCl, 3 mmol/liter NaN 3 , pH 7.4 buffer (TBS buffer).
Measurement of Cholesteryl Ester
Transfer Activity -Cholesteryl ester transfer activity was determined by quantitating the transfer of radiolabeled cholesteryl esters from 3 H-CE-LDL to unlabeled acceptor HDL or from 3 H-CE-HDL 3 to unlabeled acceptor LDL as Inhibition of CETP activity by apolipoprotein C-I previously described (6) . Human LDL and HDL were biosynthetically radiolabeled as previously described (17) . A protein fraction containing purified CETP activity, and devoided of LCAT and PLTP activities was prepared by a sequential chromatographic procedure as previously described (18) . In cholesteryl ester transfer assays, donor (cholesterol, 2.50 nmol) and acceptor lipoproteins (cholesterol, 0.62-20.00 nmol) were incubated for 3 h at 37°C in the presence of partially purified CETP (4.5 µg) in a final volume of 50 µl. Following the incubation, the d < 1.068 and the d > 1.068 g/ml fractions were separated by ultracentrifugation and transferred into counting vials containing 2 ml of scintillation fluid.
The radioactivity was assayed for 2 min in a Wallac 1410 liquid scintillation counter (Pharmacia). The recovery of total radioactivity in the d < 1.068 and in the d > 1.068 g/ml fractions was greater than 95%. Cholesteryl ester transfer rates were calculated from the known specific radioactivity of the donor and the accumulation of 3 H-CE in the d < 1.068 or the d > 1.068 g/ml acceptor fraction, after deduction of blank values from control mixtures which were incubated at 37°C without CETP. Data were expressed as the amount of cholesteryl ester transferred per ml of incubation mixture per hour (nmol/ml/h).
Delipidation of HDL Apolipoproteins -Ultracentrifugally isolated HDL were delipidated using ethanol-acetone (1:1, v/v) according to the general procedure of Jackson and Holdsworth (19) . The aqueous solution containing delipidated apolipoproteins was dialyzed overnight against TBS buffer. Western Blot Analyses -Samples were electrophoresed on SDS polyacrylamide-high density gels as decribed above and were further transferred to a nitrocellulose membrane using a Phast semi-dry electrophoretic transfer system (Pharmacia). The resulting blots were blocked overnight at 4°C with 10% low fat dried milk in TBS containing 0.1% Tween, and washed with TBS-Tween. The blots were developped by successive incubations with affinity Inhibition of CETP activity by apolipoprotein C-I purified anti-apo C-I antibodies (Biodesign) and with peroxidase-conjugated anti-goat antibodies (Sigma) as previously described (9) . Blots were finally developped using an ECL kit (Amersham).
Aminoacid Sequencing -The N-terminal sequence of protein samples was determined by automatic Edman degradation on an Applied Biosystems 473A microsequencer. Samples purified by HPLC were loaded on Polybrene-treated and precycled glass-fiber filters (23) . Phenylthiohydantoin-derivatives were identified by chromatography on a PTH C18 column (2.1 x 200 mm).
Protein Mass Spectrometry Analyses -Protein mass spectrometry analyses were carried out by using either a MALDI-TOF-MS or a single quadrupole mass detector. In the former case determination of mass was carried out as previously described (24) 
Protein and Lipid Analyses -All chemical assays were performed on a Cobas-Fara
Centrifugal Analyzer (Hoffmann-La Roche). Total cholesterol was measured by an enzymatic method using Boehringer Mannheim reagents. Protein concentration was measured using bicinchoninic acid reagent (Pierce) according to Smith et al. (25) .
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RESULTS
Differential Effects of HDL and LDL on CETP Activity -Mixtures containing
purified human CETP and various amounts of isolated plasma LDL and HDL were incubated for 3 hours at 37°C. As shown in Fig. 1A , the rate of transfer of radiolabeled cholesteryl esters from a constant amount of 3 H-CE-HDL 3 (cholesterol, 50 nmol/ml) to LDL increased gradually as the LDL cholesterol levels rose from 12.5 up to 400 nmol/ml. At a constant amount of 3 H-CE-LDL (cholesterol, 50 nmol/ml), a rise in cholesteryl ester transfer could be observed only with low amounts of unlabeled HDL acceptors, not exceeding 25 nmol/ml of HDL cholesterol. In direct contrast with LDL, and for HDL cholesterol levels greater than 25 nmol/ml, cholesteryl ester transfers were reduced in a concentration-dependent manner (Fig.   1B ). An approximately 75% inhibition of CETP activity was reached with the highest HDL cholesterol dose (400 nmol/ml) as compared to the maximal cholesteryl ester transfer rate measured with the optimal 25 nmol/ml cholesterol dose (Fig. 1B) .
Isolation and Characterization of a Lipid Transfer Inhibitor from Human Plasma HDL
-Total HDL apolipoproteins from normolipidemic human plasma were separated on a polyacrylamide gradient gel and up to thirty distinct protein fractions, with mean molecular weights ranging from approximately 80 kDa down to 2 kDa were finally obtained after electroelution in CAPS buffer (see 'Materials and Methods'). Individual protein fractions were then analysed for their ability to inhibit the CETP-mediated cholesteryl ester transfer reaction as measured from 3 H-CE-LDL towards HDL. As shown in Fig. 2 , several fractions The nearly complete blockade of the lipid transfer process that was obtained with fraction #26 contrasted clearly with the discrete, approximately 25% inhibition that was observed with the same volume of other protein fractions of larger size (Fig. 2) . Fraction #26 was then further purified and concentrated through a second passage on the preparative electrophoresis apparatus. The analysis of the protein composition of fraction #26 by denaturating gradient gel electrophoresis revealed the presence of a major protein component with an apparent molecular weight that was slightly lower than 6.5 kDa (Fig. 2) . After automatic Edman anti-apo C-I antibodies (Fig. 3) . In addition, it is noteworthy that cholesteryl ester transfer activity in control mixtures was even further increased in the presence of anti-apo C-I antibodies, with an approx. 40% increment in cholesteryl ester transfer rates in anti-apo C-Itreated mixtures as compared to controls (p < 0.05 ; Fig. 3 ). In contrast to anti-apo C-I antibodies, anti-apo C-III antibodies did not alter the inhibitory effect of fraction #26 (Fig.   3 ).
In complementary experiments, apolipoprotein C-I was completely purified by using an
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independent, chromatofocusing procedure that took advantage of the high isoelectric point of apo C-I as compared to other HDL apolipoprotein components. Purified apo C-I appeared as an homogenous band on polyacrylamide gel with the same apparent molecular weight as the main protein component of fraction #26 (Fig. 4) . Its molecular weight determined by the MSD 1100 single quadrupole mass detector was 6630 kDa, and partial analysis of the Nterminal sequence matched the apo C-I sequence (results not shown). In incubation mixtures containing LDL, HDL and purified CETP, pure apo C-I could completely block cholesteryl ester transfer activity, with an IC 50 value of approximately 100 nmol/ml (Fig. 5) .
Role of Apo C-I in Regulating the Interaction of CETP with Plasma HDL -In order
to determine the inhibitory effect of apo C-I not only as a pure apolipoprotein, but also as one component of the HDL protein moiety, the effect of total delipidated HDL apolipoproteins on CETP activity was further studied. As shown in Fig. 6 , total delipidated HDL apolipoproteins could markedly inhibit the rate of transfer of cholesteryl esters. The inhibition could be completely blocked by anti-apo C-I antibodies, whereas anti-apo C-III antibodies were without any effect.
Total native plasma HDL were subsequently passed through an anti-apo C-I affinity (Fig. 7) . however that apo F is bound almost exclusively to LDL, and not to HDL particles, and inhibitory activity could not be suppressed with anti-apo F antibodies (10) . Given that apo F has been reported to be mainly involved in the decrease in lipid transfers between VLDL and LDL, with the least effect on transfers involving HDL (32, 33, 10) , it certainly does not account for the potent inhibitory activity that is specifically associated with HDL (1, 2, 13, present study).
In order to assess the molecular basis for the inhibition of CETP activity by plasma HDL, the complete apolipoprotein pattern of HDL was fractionated by preparative electrophoresis, and resulting individual fractions were explored for their inhibitory potential.
The latter experimental approach met two important requisites. Firstly, it allowed to explore the entire HDL apolipoprotein spectrum, with apparent molecular weights of isolated proteins shown in the present study to account for most of the lipid transfer inhibitory activity that is associated with these particles, and consistent observations were made when HDL were
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isolated from plasma of distinct normolipidemic subjects. Interestingly, earlier studies
reported that approximately 85% of total functional lipid transfer inhibitory activity in human plasma is localised in the HDL fraction (13) , as is apolipoprotein C-I (34). In fact, the bulk of plasma apo C-I (approximately 80%) was shown to associate with HDL in vivo, whereas no apo C-I could be detected in LDL (34) . This peculiar distribution of apo C-I provides a direct explanation for the marked discrepancy in the ability of plasma LDL and HDL to inhibit CETP (1, 2, present study). Interestingly, a N-terminal fragment of baboon apo C-I (residues 1-38) was previously reported to suppress CETP activity in vitro (15) . However, the IC 50 value calculated with the baboon apo C-I fragment (approximately 100 µmol/l) was considerably higher than the IC 50 value reported in the present study with full length human apo C-I (approximately 100 nmol/l).
Plasma apolipoprotein C-I contains 57 residues, and it has the highest isoelectric point among the HDL apolipoproteins. Apo C-I can inhibit phospholipase A2 (35) and hepatic lipase (36) , and it can stimulate cell growth (20) . It can also activate LCAT, however with much less efficiency than apo A-I (37, 38) . Among apo C's, apo C-I was shown to be the most potent inhibitor of the apo E-mediated binding of β-VLDL to the LDL receptor and the LDL receptor-related protein (39) (40) (41) . Although in vivo studies in apo C-I transgenic mice susbtantiated the former observations, studies in homozygous apo C-I deficient mice led unexpectedly to opposite conclusions (42) (43) (44) . In fact, both apo C-I overexpression and apo C-I deficiency led to markedly increased levels of atherogenic VLDL-and LDL-like particles (42) (43) (44) . These observations suggest therefore that the function of apo C-I may not be restricted to the regulation of the cellular uptake of potentially atherogenic lipoproteins.
Since the present study ascribed a key role to apo C-I in regulating plasma cholesteryl ester transfer activity, previous in vivo studies in apo C-I transgenic mice and apo C-I knocked out
mice may well not have been fully conclusive due to the lack of substantial levels of active CETP in this animal species (45, 46) .
In conclusion, results of the present studies demonstrated that apolipoprotein C-I accounts for most of the CETP inhibitory activity that is associated with human plasma HDL.
In contrast to most other putative apolipoprotein inhibitors, apo C-I was proved to meet all the following criteria: i) apo C-I inhibitory activity is specifically localised in HDL, and not in LDL; ii) it constitutes a potent inhibitor of CETP, with the exclusion of activating potential;
iii) a complete blockade of CETP activity can be reached with elevated inhibitor doses; iv) and increasing amounts of LDL acceptors (cholesterol, 12.5-400 nmol/ml) (Fig. 1A) or a constant amount of 3 H-CE-LDL donors (cholesterol, 50 nmol/ml) and increasing amounts of HDL acceptors (cholesterol, 12.5-400 nmol/ml) (Fig. 1B) . Mixtures were incubated for 3 h at 37°C in the presence of partially purified CETP (4.5 µg) in a final volume of 50 µl.
Cholesteryl ester transfer rates were determined as described in 'Materials and Methods'.
Each point represents the mean +/-S.D. of triplicate determinations. 50-µl mixtures containing 3 H-CE-LDL (cholesterol, 50 nmol/ml), HDL (cholesterol, 200 nmol/ml) and partially purified CETP (4.5 µg) were incubated for 3h at 37°C in the presence of increasing amounts of purified apo C-I (0-3.7 µg/ml). Cholesteryl ester transfer rates were calculated as described under 'Materials and Methods', and data were expressed as relative to control. Each point represents the mean +/-S.D. of triplicate determinations. 
